To assess the therapeutic efficacy of TGF‐β blockade in comparison with immune checkpoint inhibition, EL4 lymphoma‐bearing mice were treated with anti‐TGF‐β antibody or a combination of anti‐PD‐1 and anti‐CTLA‐4 antibodies (Figure 7E). Here, PDCD1 is linked to lymphoma.